StockData
Silence Therapeutics plc logo

Silence Therapeutics plc (SLN) stock

SLNNasdaqPharmaceutical PreparationsAlso trades as SLNCF
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 7/30
$19.80−0.03 (-0.15%)

Close on Nov 16, 2026Market cap $935.48MP/E –Yield –

Silence Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Silence Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $36.32M, down 55.2% year over year. For fiscal 2025 it was $67.75M, down 0.2% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$67.75M-0.2%
FY2024Dec 31, 2024$67.88M+19.2%
FY2023Dec 31, 2023$56.94M+30.7%
FY2022Dec 31, 2022$43.55M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$9.30M-54.7%
Q2 FY2026Jun 30, 2026$9.15M-48.2%
Q1 FY2026Mar 31, 2026$9.12M-56.2%
Q4 FY2025Dec 31, 2025$8.75M-60.4%
Q3 FY2025Sep 30, 2025$20.54M+1.9%
Q2 FY2025Jun 30, 2025$17.65M+27.9%
Q1 FY2025Mar 31, 2025$20.81M+75.7%
Q4 FY2024Dec 31, 2024$22.08M–
Q3 FY2024Sep 30, 2024$20.16M–
Q2 FY2024Jun 30, 2024$13.80M–
Q1 FY2024Mar 31, 2024$11.85M–

More Silence Therapeutics figures

See a number that looks wrong?